OMB157A
Drug
Novartis Pharma AG
Total Payments
$14,902
Transactions
7
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $14,902 | 7 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,656 | 3 | 98.3% |
| Travel and Lodging | $206.75 | 3 | 1.4% |
| Food and Beverage | $39.16 | 1 | 0.3% |
Ad
Manufacturing Companies
- Novartis Pharma AG $14,902
Product Information
- Type Drug
- Total Payments $14,902
- Total Doctors 3
- Transactions 7
About OMB157A
OMB157A is a drug associated with $14,902 in payments to 3 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2018 to 2018. In 2018, $14,902 was paid across 7 transactions to 3 doctors.
The most common payment nature for OMB157A is "Consulting Fee" ($14,656, 98.3% of total).